Heritage, Ipca Enter Agreement for Generic Pharma Products
Posted on: Tuesday, 28 August 2007, 12:16 CDT
Heritage Pharmaceuticals and Ipca Laboratories have struck a deal for the development, supply and marketing of generic pharmaceutical products for the US prescription drug market.
Under the agreement, Ipca will develop and register selected products for US ANDA submission, while Heritage will retain sales and marketing rights to such products. The parties shall share net profits from the sales proceeds post-launch.
Heritage president & CEO, Jeffrey Glazer, stated: "These types of agreements enable Heritage to leverage our business model of strategic outsourcing to obtain a 'virtually vertical' supply chain of quality generic products as we continue to expand our product offerings."
Heritage launched its US label in 2006 and currently markets three products over 10 SKU's. The company will continue to introduce its acquired multi-source generic product line during 2007-08.
Source: Datamonitor
Related Articles
- Heritage Village Is the Latest Project in the Successful Partnership Between AUI Contractors and the City of Hurst, Texas
- High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected From Generic Competition Until 2011
- Generic Medical Devices, Inc. Of Gig Harbor, Wash. Launches
- Governors Seek Generic Guidelines
- Governors Ask About Generic Treatments
- Pharmaceutical Production in Hungary is Specialised in the Production of Generic Drugs With Nearly 20 Original Molecules Developed During the Last Decade
- FDA Won't Release Generic Insulin Guide
- Brazil Expects Drug Makers to Cut Prices
- Generic AIDS Drug Could Be Made by March
- African Countries Close to AIDS Drug
 |
 |
User Comments (0)
RSS Feeds